ArticleOpen forum infectious diseases2026
Implementation of Long-Acting Cabotegravir/Rilpivirine in US HIV Care Settings: Results From a National Survey of Frontline Clinicians.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-acting cabotegravir/rilpivirine is the first and only complete injectable HIV regimen; it was approved in the United States in 2021 for individuals who are virologically suppressed. While clinical trials have demonstrated efficacy, real-world implementation remains underexplored. We conducted a cross-sectional survey between July and August 2024 among members and credentialed clinicians of the American Academy of HIV Medicine who were frontline HIV providers. Overall, long-acting cabotegravir/rilpivirine has been widely adopted in US HIV care, but structural, financial, and clinical barriers persist. Standardized guidance is needed to expand data in youth, persons with obesity, and other special populations. Strategies to address health care infrastructure barriers are essential to optimize uptake and equitable access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.